*Gonadotropin-releasing hormone (GnRH) antagonists are synthetic analogs of gonadotropin-releasing hormone, which is produced by the hypothalamus and controls the secretion of follicle stimulating hormone (FSH) and luteinizing hormone (LH) by the anterior pituitary. Gonadotropin-releasing hormone antagonists bind to gonadotropin-releasing hormone receptors and decrease the effect of gonadotropin-releasing hormone.
In men, gonadotropin-releasing hormone antagonists inhibit the release of luteinizing hormone, and consequently less testosterone is produced. Testosterone stimulates the growth of many forms of prostate cancer. Gonadotropin-releasing hormone antagonists are used to treat prostate cancer as by reducing the levels of testosterone the size of prostate cancer is reduced.
Gonadotropin-releasing hormone antagonists are used to treat women undergoing fertility treatment. It prevents early release of luteinizing hormone (LH) and premature ovulation in women being administered follicle-stimulating hormone (FSH) when preparing for in-vitro fertilization.
| Name | Updated |
|---|---|
| Ganirelix acetate (Ganirelix [ ga-ni-rel-ix ]) | 15-Aug-2023 |
| Ganirelix (Ganirelix [ ga-ni-rel-ix ]) | 15-Aug-2023 |
| Cetrorelix (injectable) (Cetrorelix (injectable) [ se-troe-rel-ix ]) | 15-Aug-2023 |
| Relugolix (Relugolix [ rel-ue-goe-lix ]) | 12-Aug-2023 |
| Orilissa (Elagolix [ el-a-goe-lix ]) | 05-Aug-2023 |
| Cetrotide (injectable) (Cetrorelix (injectable) [ se-troe-rel-ix ]) | 05-Aug-2023 |
| Plenaxis (Abarelix [ a-bar-eh-lix ]) | 13-Jul-2023 |
| Orgovyx (Relugolix [ rel-ue-goe-lix ]) | 11-Jul-2023 |
| Firmagon (Degarelix [ deg-a-rel-ix ]) | 10-Jul-2023 |
| Elagolix (Elagolix) | 10-Jul-2023 |
| Degarelix (Degarelix [ deg-a-rel-ix ]) | 10-Jul-2023 |